The endopeptidase inhibitor, candoxatril, and its therapeutic potential in the treatment of chronic cardiac failure in man

Bibliography

• WOOD P: Diseases of The Heart and Circulation. Eyre and Spottiswoode, London (1968):291.
   Google Scholar
• PACKER M: Pathophysiology of chronic heart failure. Lancet (1992) 340:88–92.
   PubMed Web of Science ®Google Scholar
• NICHOLLS DP, ONUOHA GN, MCDOWELL G et al.: Neuro-endocrine changes in chronic cardiac failure. Basic Res. Cardiol. (1996) 91:13–20.
   PubMed Web of Science ®Google Scholar
• MCDOWELL G, SHAW C, BUCHANAN KD, NICHOLLS DP:The natriuretic peptide family. Eur.J. Clin. Invest. (1995) 25:291–298.
   PubMed Web of Science ®Google Scholar
• LEVIN ER, GARDNER DG, SAMSON WK: Natriuretic pep-tides. Lancet (1998) 339:321–328.
   Google Scholar
• BRENNER BM, BALLERMAN BJ, GUNNING ME et al.: Di-verse biological actions of ANP. Physiol. Rev. (1990) 20:665–699.
   Google Scholar
• FUJITA T, ITO Y, NODA H et al: Vasodilatory actions ofalpha-human atrial natriuretic peptide and high Ca2+ effects in normal man. Er. J. Clin. Invest. (1987) 80:832–840.
   Web of Science ®Google Scholar
• EDWARDS BS, ZIMMERMAN RS, SCHWAB TR, HEUBLEIN DM, BURNETT JC: Atrial stretch, not pressure, is the principal determinant controlling the release of atrial natriuretic factor. Circ. Res. (1988) 62:191–195.
   PubMed Web of Science ®Google Scholar
• STEELE IC, MCDOWELL G, MOORE AL et al: Responses of atrial natriuretic peptide and brain natriuretic peptide to exercise in patients with chronic heart failure and normal controls. Er. J. Clin. Invest. (1997) 27:270–276.
   PubMed Web of Science ®Google Scholar
• YANDLE TG, RICHARDS AM, NICHOLLS MG, CUNEO R, ES-PINER EA, LIVESEY JH: Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic pep-tide in man. Life Sci. (1986) 38:1827–1833.
   PubMed Web of Science ®Google Scholar
• ANAND-SRIVASTAVA MB, TRACHTE GJ: Atrial natriu-retic factor receptors and signal transduction mecha-nisms. Pharmacol. Rev. (1993) 45:455–497.
   PubMed Web of Science ®Google Scholar
• MUKOYAMA M, NAKOO K, HOSODA K et al.: Brain natriuretic peptide as a novel cardiac hormone in hu-mans. J. Clin. Invest. (1991) 87:1402–1412.
   PubMed Web of Science ®Google Scholar
• CHEUNG BMY, DICKERSON JEC, ASHBY MJ, BROWN MJ,BROWN J: Effects of physiological increments in hu-man atrial natriuretic peptide and human brain natriuretic peptide in normal male subjects. Clin. Sci. (1994) 86:723–730.
   PubMed Web of Science ®Google Scholar
• LANG CC, MOTWANI JG, COUTIE WJ, STRUTHERS AD: Clearance of brain natriuretic peptide in patients with chronic cardiac failure: indirect evidence for a neutral endopeptidase mechanism but against an atrial natriu-retic peptide clearance receptor mechanism. Clin. Sci. (1992) 82:619–623.
   PubMed Web of Science ®Google Scholar
• KOMATSU Y, NAKAO K, SUGA S eta].: C-type natriuretic peptide (CM in rats and humans. Endocrinology (1991) 129:1104–1106.
   Google Scholar
• CLAVELL AL, STINGO AJ, WEI CM, HEUBLEIN DM, BUR-NETT JC: C-type natriuretic peptide: a selective cardio-vascular profile. Am. J. Physiol (1993) 264:R290–295.
   PubMed Web of Science ®Google Scholar
• MOLINA CR, FOWLER MB. MCCRORY S et al.: Hemody-namic, renal and endocrine effects of atrial natriuretic peptide infusion in severe heart failure. J. Am. Coll. Car-diol. (1988) 12:175–186.
   Google Scholar
• YOSHIMA M, YASUE H, MORITA E et al.: Hemodynamic, renal and hormonal responses to BNP in patients with congestive heart failure. Circulation (1991) 84:1581–1588.
   PubMed Web of Science ®Google Scholar
• ROQUES BP, NOBLE F, DAUGE V et al: Neutral endopep-tidase 24.11: structure, inhibition and experimental and clinical pharmacology. Pharmacol. Rev. (1993) 45:87–146.
   Google Scholar
• AVIV R, GURBANOV K, HOFFMAN A, BLUMBERG S, WI-NAVER J: Urinary neutral endopeptidase 24.11 activity. Modulation by chronic salt loading. Kidney Int. (1995) 47:855–860.
   Google Scholar
• WILKINS MR, UNWIN RJ, KENNY AJ: Endopeptidase 24.11 and its inhibition: potential therapeutic agents for edematous disorders and hypertension. Kidney Int. (1993) 43:273–285.
   Google Scholar
• ALBRIGHTSON CR, PULLEN M, WU HL et al.: Thrombinmediated down regulation of endothelial receptors in mesangial cells coincides with down regulation of neutral endopeptidase activity. Mol. Pharmacol. (1995) 47:1156–1163.
   PubMed Web of Science ®Google Scholar
• GRAF K, KOEHNE P, GRAFE M, ZHANG MH, ACHSCH-WELL W, FLECK E: Regulation and differential expres-sion of neutral endopeptidase 24.11 in human endothelial cell. Hypertension (1995) 26:230-235. 24.Clinical Investigators Manual. Pfizer Central Research (January 1991).
   Google Scholar
• KAYE B, BREARLEY CJ, CURRAN NJ et al.: Formation andpharmacokinetics of the active drug candoxatrilat in mouse, rat, rabbit, dog, man following administration of the prodrug candoxatril. Xenobiotica (1997) 27:1091–1102.
   PubMed Web of Science ®Google Scholar
• NORTHRIDGE DB, ALABASTER CT, CORNELL JMC et al.:Effect of UK69578: a novel atriopeptidase inhibitor. Lancet (1989) 2:591–593.
   PubMed Web of Science ®Google Scholar
• O'CONNELL JE, JARDINE AG, DAVIES DL, MCQUEEN J,CONNELL JM: Renal and hormonal effects of chronic inhibition of neutral endopeptidase in normal man. Clin. Sci. (1993) 85:19–26.
   PubMed Web of Science ®Google Scholar
• RICHARDS M, ESPINER E, FRAMPTON C et al.: Inhibitionof endopeptidase EC 24.11 in humans. Renal and endo-crine effects. Hypertension (1990) 16:269–276.
   Google Scholar
• RICHARDS AM, WITTERT G, ESPINER EA et al.: EC 24.11inhibition in man alters clearance of atrial natriuretic peptide. J. Clin. Endocrinol. Metab. (1991) 72:1317–1322.
   Google Scholar
• SAGNELLA GA, SINGE DRJ, MARKANDU ND, BUCKLEY MG, MACGREGOR GA: Is atrial natriuretic peptide guanosine 3'- 5' cyclic monophosphate coupling a de-terminant of urinary sodium excretion in essential hy-pertension. J. Hypertens. (1992) 10:349–354.
   PubMed Web of Science ®Google Scholar
• RICHARDS AM, WITTERT GA, ESPINER EA et al.: Effect ofinhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. Circ. Res. (1992) 71:1501–1507.
   Google Scholar
• RICHARDS AM, WITTERT G, ESPINER EA eta].: Inhibitionof endopeptidase 24.11 in man, renal, rendcrine and haemodynamic effects. Hypertension (1991) 17:403.
   Google Scholar
• SAGNELLA GA, MARKANDU ND, BUCKLEY MG: Hormo-nal and renal responses to neutral endopeptidase in-hibition in normal humans on a low and on a high sodium intake. Eur. j Clin. Invest. (1995) 25:165–170.
   PubMed Web of Science ®Google Scholar
• O'CONNELL JE, JARDINE A, DAVIDSON G et al. UK 79300 and orally active atriopeptidase inhibitor raises plasma atrial natriuretic peptide and is natriuretic in essential hypertension. J. Hypertens. (1989) 7:923.
   Google Scholar
• KROMER EP, ELSNER D, KAHLES HW, RIEGGER GA: Effect of atriopeptidase inhibitor UK79300 on left ventricu-lar hydraulic load in patients with congestive heart failure. Am. J. Hypertens. (1991) 4:460–463.
   PubMed Web of Science ®Google Scholar
• NORTHRIDGE DB, JARDINE AG, FINDLEY IN et al.: Inhibi-tion of metabolism of atrial natriuretic factor causes diuresis and natriuresis in chronic heart failure. Am. J. Hypertens. (1990) 3:682–687.
   PubMed Web of Science ®Google Scholar
• GOOD JM, PETERS M, WILKINS M et al.: Renal responses to candoxatrilat in patients with heart failure. J. Am. Coll. Cardiol. (1995) 25:1273–1281.
   PubMed Web of Science ®Google Scholar
• KROMER EP, KEAHLES HW, ELSNER D, RIEGGER GAJ: Ef-fect of atriopeptidase inhibitor UK 79300 on aortic im-pedance in patients with congestive heart failure. Circulation (1989) 80:11–630.
   Google Scholar
• ELSNER D, MUNTZE A, KROMER EP, RIEGGER GAJ: Effec-tiveness of endopeptidase inhibition (candoxatril) in congestive heart failure. Am. J. Cardiol. (1992) 70:494–498.
   PubMed Web of Science ®Google Scholar
• MOTWANI JG, LANG CC, ALLEN MJ, JOHNSTEN HF, STRUTHERS AD: Dose ranging effect of candoxatril on elimination of exogenous atrial natriuretic peptide. Clin. Pharmacol. Ther. (1993) 54:661–669.
   PubMed Web of Science ®Google Scholar
• LANG CC, MOTWANI J, COUTIE WJ, STRUTHERS AD: In-fluence of candoxatril on plasma brain natriuretic peptide in heart failure. Lancet (1991) 338:255.
   PubMed Web of Science ®Google Scholar
• NORTHRIDGE DB, JARDINE A, HENDERSON B, DILLY SG,DARGIE HJ: Increased circulating atrial natriuretic fac-tor concentrations in patients with chronic heart fail-ure after inhibition of neutral endopeptidase: effects on diastolic function. Br. Heart J. (1992) 68:387–391.
   PubMedGoogle Scholar
• KENTSCH M, OTTER W, DRUMMER et al.: Neutral en-dopeptidase 24.11 inhibition may not exhibit benefi-cial haemodynamic effects in patients with congestive heart failure. Er. J. Clin. Pharmacol (1996) 51:269–272.
   Google Scholar
• HARRIS P: Congestive heart failure: central role of thearterial blood pressure. Br. Heart J. (1997) 58:190–203.
   Google Scholar
• MAGUIRE SM, NUGENT AG, MCGURK C, JOHNSTON GD,NICHOLLS DP: Abnormal vascular responses in human chronic cardiac failure are both endothelium-dependent and endothelium-independent. Heart (1998) 80:141–145.
   PubMed Web of Science ®Google Scholar
• JOHNSTON GD, NICHOLLS DP, KONDOWE GB, FINCH MB: Comparison of the acute vascular effects of frusemide and bumetanide. Br. J. Clin. Pharmacol (1986) 21:359–364.
   PubMed Web of Science ®Google Scholar
• NORTHRIDGE DB, JACKSON NC, METCALFE MJ, DARGIEHJ: Effects of candoxatril, a novel endopeptidase in-hibitor, compared to frusemide in heart failure. Jr. J. Merl. Sci. (1994) 163:397.
   Google Scholar
• MCDOWELL G, COUTIE WJ, SHAW C, BUCHANAN KD,STRUTHERS AD, NICHOLLS DP: The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides. Br. J. Clin. Pharmacol. (1997) 43:329–332.
   PubMed Web of Science ®Google Scholar
• FERRO CJ, HAYNES WG, WEBB DJ: Role of neutral en-dopeptidase in control of peripheral vascular tone in man. Br. J. Clin. Pharmacol. (1996) 41:440P–441P.
   Google Scholar
• ANDO SI, RAHMAN MA, BUTLER GC, SENN BL, FLORAS JS: Comparison of candoxatril and atrial natriuretic fac-tor in healthy men. Effects on haemodynamics, sym-pathetic activity, heart rate variability and endothelin. Hypertension (1995) 26:1160–1166.
   Google Scholar
• NORTHRIDGE DB, MCMURRAY J, DARGIE HJ: A multi-centre double-blind, placebo controlled trial compar-ing neutral endopeptidase inhibition with converting enzyme inhibition in chronic heart failure. Jr. J. Med. ScL (1995) 164:72–73.
   Google Scholar
• NEWBY DE, MCDONAGH T, CURRIE PF, BOON NA, DAR-GTE HJ: Candoxatril improves exercise capacity in pa-tients with chronic heart failure receiving angiotensin converting enzyme inhibition. J. Am. Coll. Cardiol (1997) 29:169A.
   Web of Science ®Google Scholar
• CLELAND JGF: Chronic haemodynamic effects of can-doxatril - a multicentre dose-ranging study. J. Am. Coll. Cardiol. (1997) 29:169A.
   Google Scholar